Navigation Links
Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
Date:5/28/2013

Westlake Village, CA (PRWEB) May 28, 2013

Cynvenio Biosystems, Inc., a cancer diagnostics company focused on the molecular analysis of tumor biomarkers derived from whole blood, today announced that clinical data from two research collaborations in breast and prostate cancer will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 taking place May 31-June 4, 2013 in Chicago. These data highlight the company’s progress in the molecular analysis of circulating tumor cells (CTC) by next generation sequencing.

The breast cancer study was completed with Fox Chase Cancer Center and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, Pennsylvania. The prostate cancer study was completed in collaboration with the Norris Comprehensive Cancer Center at the University of Southern California in Los Angeles.

Both studies demonstrate the feasibility of sequencing CTC populations isolated by LiquidBiopsy to discover disease-associated mutations. The potential of this approach is to monitor patients frequently over their entire cancer care cycle to determine the most appropriate treatment, measure response to therapy and, ultimately, screen the population for disease via a simple blood draw.

"These two studies further demonstrate the importance of applying new technology to the molecular analysis of cancer," said André de Fusco, president and CEO of Cynvenio Biosystems, Inc. "In oncology, as in all fields, better decisions are based on frequent analysis of the most up-to-date information - not less - and our goal is to place this capability within reach of every doctor and patient."

The schedule for poster presentations by Cynvenio Biosystems and its collaborators is:

Time and Date: 1:15-5:00 p.m. Saturday, June 1
Title: Classifying circulating mutation bearing tumor cells from breast cancer patients
Abstract Number: 115791
Poster Board Number: 6C
Session: General Poster Session: Breast Cancer
Type: Poster Session
Location: South Hall 2A
Presenters: William Strauss*, Paul W. Dempsey*, Jessamine Winer-Jones*, Catherine Bingham†, R. Katherine Alpaugh†, Massimo Cristofanilli‡; *Cynvenio Biosystems, Inc., Westlake Village, CA; †Fox Chase Cancer Center, Philadelphia, PA; ‡Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA.

Time and Date: 1:15-5:00 p.m. Monday, June 3
Title: Targeted Next Generation Sequencing (NGS) of Circulating Tumor Cells (CTCs) in Hormone-Sensitive Prostate Cancer
Abstract: 11040
Poster Board Number: 43C
Session: General Poster Session: Genitourinary Cancer, Prostate Cancer
Location: South Hall 2A
Presenters: Stephen Liu†, Paul Dempsey*, William Strauss*, Yucheng Xu†, Tong Xu†, Jacek Pinski†, Tanya Dorff†, David Quinn†, André de Fusco*, Tim Triche†, Janine McMurdie?, Amir Goldkorn†; *Cynvenio Biosystems, Inc., Westlake Village, CA; ?Life Technologies, Inc., Carlsbad, CA.; †University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.

About Cynvenio Biosystems, Inc.

Cynvenio Biosystems, Inc. is a molecular diagnostics company dedicated to the early detection and targeted treatment of cancer. Cynvenio has developed and deployed the LiquidBiopsy® system to enable realtime monitoring of tumor cell-associated mutations from a simple blood draw. This information can be used by physicians, academic centers, and drug developers to define treatment cycles for individual patients, efficiently select patients for drug trials and monitor patient response at any stage of disease.

Cynvenio’s CLIA service lab is based in Westlake Village, California. To find out more about the company please visit: http://www.cynvenio.com and http://www.liquidbiopsy.com.

LiquidBiopsy is a registered trademark of Cynvenio Biosystems, Inc.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10770579.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
2. Indigo Biosystems Among “Best Places to Work” in Indiana
3. Indigo Biosystems Nominated for Two TechPoint Mira Awards for Technology Excellence and Innovation
4. Genesis Biosystems Unveils Innovative Skin Treatment at Esthétique SPA International Trade Show
5. Lucas Bagnell Varga LLC Secures $17.4 Million Award For Former Applied Biosystems Executives
6. Aushon BioSystems and AH diagnostics unterzeichnen Distributionsvertrag für Skandinavien
7. Aushon BioSystems and AH diagnostics Sign Distribution Deal for Scandinavia
8. AyoxxA Biosystems Closes Series A Financing Round
9. Aushon BioSystems Appoints Martin Verhoef Chief Executive Officer
10. Ahram Biosystems Announces Launch of the New Economy Model F1-12 of Its Palm PCR Series
11. Lexicon To Present At The Deutsche Bank dbAccess Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... DIEGO , Feb. 24, 2017  OncoSec Medical ... cancer immunotherapies, will host a Key Opinion Leader event ... as an oral and poster presentation at the upcoming ... plan. The KOL event will be held in-person and ... PM EST / 9:00 AM PST at the Lotte ...
(Date:2/23/2017)... /PRNewswire/ - The Fight Against Cancer Innovation Trust (FACIT) ... pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has ... Johnson Innovation – JJDC, Inc. (JJDC) as the lead ... Biotechnology Partners, and Genesys Capital, as well as founding ... ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
(Date:2/8/2017)... LONDON , Feb. 7, 2017 Report ... $12.5 billion by 2021 from $8.3 billion in 2016 ... from 2016 to 2021. Report Includes - An ... of global market trends, with data from 2015 and ... through 2021. - Segmentation of the market on the ...
Breaking Biology News(10 mins):